

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/540,998	First Named Inventor: Leung et al.
371 Filing Date: June 28, 2005	Attorney Docket No.: 100851-1P US
Examiner: BARKER, Michael P.	Group Art Unit: 1626
Customer No.: 22466	Confirmation No.: 9023
Title: CB 1/CB 2 Receptor Ligands and Their Use in the Treatment of Pain	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO THE RESTRICTION REQUIREMENT

Sir:

The present Response is filed in regard to the Restriction Requirement dated September 7, 2007 in connection with the above-identified patent application.

In the Restriction Requirement, the Examiner restricted pending claims into seven groups:

Group I: Claims 1-6, 10, 15 and 16 are drawn to compounds, compositions, and a method of treatment using the compounds of formula I.

Group II: Claims 7 and 10 are drawn to compounds of formula II.

Group III: Claims 8 and 10 are drawn to compounds of formula III or IV.

Group IV: Claims 9 and 10 are drawn to compounds of formula V.

Group V: Claim 17 is drawn to a process for preparing compounds of formula X.

Group V(?): Claim 18 is drawn to a process for preparing compound of formula XIII.

Group XV: Claim 19 is drawn to a process for preparing compound of formula XIII(?).

Applicants hereby elect Group I.

Applicants also want to point out that the Examiner mentioned two Group Vs in the instant Restrict requirement. Applicants respectfully ask the Examiner to assign a different Group number for one of these inventions for the record. In addition, Applicants want to point out in Group XV, claim 19 is directed to a process for preparing a compound of formula XV. For

Application No. 10/540,998
Response Dated: September 19, 2007
Reply to Restriction Requirement of September 7, 2007

the record, Applicants respectfully ask the Examiner to acknowledge that it is indeed a typographical error.

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100851-1P US.

Respectfully submitted,
/Jianzhong SHEN, Reg.#48076 /

Name: Jianzhong Shen
Dated: 9/19/2007
Reg. No.: 48076
Phone No.: 302-886-8854
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437